(Q38069890)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Changhai Ding

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

Changhai Ding

1 reference

28 August 2017

Xingzhong Jin

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

27 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

315-322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

Rheumatoid arthritis: diagnosis and management

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

B cells move to centre stage: novel opportunities for autoimmune disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

B cell immunobiology in disease: evolving concepts from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

B-cell-targeted therapy for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

BAFF AND APRIL: a tutorial on B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Infections associated with tumor necrosis factor-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

The discovery and development of belimumab: the anti-BLyS-lupus connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.758248

10.1517/14712598.2012.758248

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23268610%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference